Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) took place on 2–4 October 2026, in Washington DC. At this event, the world’s leading clinical researchers in MDS & MPNs shared their perspectives on how to place the evolving understanding of these hematological malignancies in a clinical context to optimize clinical care.
iwMPN 2026
The 4th International Workshop on MDS & MPNs
01–04 October 2026 | Washington DC, USA
The 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) took place on 2–4 October 2026, in Washington DC. At this event, the world’s leading clinical researchers in MDS & MPNs shared their perspectives on how to place the evolving understanding of these hematological malignancies in a clinical context to optimize clinical care.
Explore roundtable discussions & interviews
View all videos
Endpoints in MPN: where have we been and where are we going
Patient-centered outcomes in MPNs: What matters most
Aligning scientific innovation, patient experience, and regulatory standards
Innovation
Keynote talk
Targeted therapies: CALR, JAK-selective and beyond
Frontline myelofibrosis combination strategies
Second-line myelofibrosis: Sequencing and positioning
Polycythemia vera and essential thrombocythemia: Emerging agents and targets
Systemic mastocytosis: Rapidly evolving targeted therapy
Keynote talk - BPDCN
From CHIP to blast phase
MDS/MPN overlaps and CMML
Endpoints in MPN: where have we been and where are we going
Current endpoint landscape in MPN clinical trials
Prithviraj Bose The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon
Patient-centered outcomes in MPNs: What matters most
Reflections of a PV patient after living for 15 years with the disease
Coming soon
Beyond spleen and symptoms: Evolving MPN clinical trials and endpoints to improve patient outcomes with real-world evidence
David Shoultz University of Washington, Seattle, WA, United States
Coming soon
Aligning scientific innovation, patient experience, and regulatory standards
Role of molecular endpoints
Jennifer O'Sullivan Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Coming soon
How best to integrate symptoms and QoL: beat ruxolitinib or non-inferior
Ruben Mesa Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, United States
Coming soon
Spleen response – what parameter?
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Coming soon
Anemia benefit
Abdulraheem Yacoub University of Kansas Medical Center, Kansas City, KS, United States
Coming soon
Abolishing venesection vs complete haematological response
Marina Kremyanskaya Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Coming soon
Innovation
Emerging novel targets: a focus on G6B
Bethan Psaila University of Oxford, Oxford, United Kingdom
Coming soon
Are we ready to mainline AI?
Sanam Loghavi The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon
Wearable devices data and novel approaches to digital data capture
Patrick Harrington Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Coming soon
Targeted therapies: CALR, JAK-selective and beyond
Latest on CALR biology
Shannon Elf University of Utah School of Medicine, Salt Lake City, UT, United States
Coming soon
Targeting mutant CALR with INCA033989 latest data
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Coming soon
Type II JAK inhibitors: AJ1-11095 – what should we expect
Gabriela Hobbs Massachusetts General Hospital, Boston, MA, United States
Coming soon
Flonoltinib JAK/CDK/FLT3
Bing Li Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Coming soon
Frontline myelofibrosis combination strategies
Pelabresib
Raajit Rampal Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Coming soon
Selinexor
Nikolai Podoltsev Yale School of Medicine, New Haven, CT, United States
Coming soon
Navtemadlin
Pankit Vachhani The University of Alabama at Birmingham, Birmingham, AL, United States
Coming soon
What treatment for a low-risk MF in 2026
Alexander Coltoff Medical University of South Carolina, Charleston, SC, United States
Coming soon
Second-line myelofibrosis: Sequencing and positioning
Nuvisertib
Joseph Scandura Weill Cornell Medicine, New York, NY, United States
Imetelstat
Andrew Kuykendall Moffitt Cancer Center, Tampa, FL, United States
The potential role of tasquinimod in myelofibrosis
Lucia Masarova The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Elritercept & Luspatercept
Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
DISC-0974
Rupali Bhave Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC, United States
Polycythemia vera and essential thrombocythemia: Emerging agents and targets
Is ruxolitinib ready for front line therapy in PV?
Steffen Koschmieder Aachen University Hospital, Aachen, Germany
Coming soon
Bomedemstat in ET and PV
Lindsay Rein Duke University Medical Center, Durham, NC, United States
Coming soon
Where is the unmet need in ET?
Douglas Tremblay Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Coming soon
Rusfertide in PV: where does it fit in an evolving treatment landscape?
Naveen Pemmaraju The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon
Systemic mastocytosis: Rapidly evolving targeted therapy
Considerations on how to evolve systemic mastocytosis response criteria in the KIT inhibitor era
Jason Gotlib Stanford University School of Medicine, Stanford, CA, United States
Coming soon
The evolving landscape of therapy for indolent systemic mastocytosis
Lindsay Rein Duke University Medical Center, Durham, NC, United States
Coming soon
Updates in the treatment of AdvSM
Daniel DeAngelo Dana-Farber Cancer Institute, Boston, MA, United States
Coming soon
Keynote talk
Exciting progress and major updates in BPDCN for 2026 and beyond
Naveen Pemmaraju The University of Texas MD Anderson Cancer Center, Houston, TX, United States
From CHIP to blast phase
Clonal evolution in MPN how often to screen, when to act and what to do
Paola Guglielmelli University of Florence, Florence, Italy
Accelerated and blast phase management including fit and unfit patients
Vikas Gupta Princess Margaret Cancer Centre, Toronto, Canada
Precision Interventional Opportunities in CH/CCUS
Kelly Bolton Washington University in St. Louis, St. Louis, MO, United States
MDS/MPN overlaps and CMML
JAK inhibitors and evolving therapies for MDS/MPN overlaps
Abdulraheem Yacoub University of Kansas Medical Center, Kansas City, KS, United States
Response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions
William Shomali Stanford University School of Medicine, Stanford, CA, United States
Improving prognostication in CMML
Luca Lanino Yale School of Medicine, CT, United States
Oral HMAs for CMML
Daniel Wiseman The Christie NHS Foundation Trust, Manchester, United Kingdom
CMML response criteria
Somedeb Ball Vanderbilt University Medical Center, Nashville, TN, United States
The iwMDS/MPN 2026 meeting was supported by:
